2018

Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Results from the NIVOREN GETUG-AFU 26 study.

Congress : ASCO

Authors : Laurence Albiges, Sylvie Negrier, Cécile Dalban, Gwenaelle Gravis, Christine Chevreau, Stephane Oudard, Brigitte Laguerre, Philippe Barthelemy, Delphine Borchiellini, Marine Gross-Goupil, Lionnel Geoffrois, Meryem Brihoum, Bernard Escudier, GETUG; 

Experts group or program : GETUG

 

NIVOREN GETUG AFU 26 study, is a French multicenter prospective study to evaluate safety and efficacy of Nivolumab (N) in a broad “real world setting” in mRCC after failure of 1 or 2 tyrosine kinase inhibitors.

En savoir plus